文献速递肿瘤 PET/CT

两种组织型转谷氨酰胺酶PET示踪剂在原位肿瘤异种移植模型中的体内评价

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.
PubMed 文献 · EJNMMI Res · 2018-05-25

在乳腺癌MDA-MB-231肿瘤异种移植模型中,[11C]1肿瘤摄取低(40-60分钟约0.5 %ID/g)且洗脱较快,[18F]2肿瘤摄取随时间稳定升高(40-60分钟约1.7 %ID/g)。预先给予TG2抑制剂ERW1041E可降低肿瘤放射性浓度,使用未标记2时抑制效果增强。作者认为[11C]1在该模型中靶向TG2的潜力似乎不足,而[18F]2实现了TG2靶向,可用于未来研究。

要点

  • [11C]1肿瘤摄取低且洗脱较快,在该模型中靶向TG2的潜力似乎不足。
  • [18F]2肿瘤摄取随时间稳定升高,实现了TG2靶向。
  • 预先给予ERW1041E可降低肿瘤放射性浓度,使用未标记2时抑制效果增强。

核心结论

  • [11C]1在该模型中靶向TG2的潜力似乎不足,而[18F]2实现了TG2靶向。
  • 作者认为[18F]2可用于未来研究以阐明活性组织型转谷氨酰胺酶在疾病中的作用。

研究设计与样本

  • 在乳腺癌(MDA-MB-231)肿瘤异种移植模型中进一步评价两种放射性标记的不可逆TG2抑制剂。

主要发现

  • [11C]1和[18F]2在SCID小鼠中的代谢稳定性与先前报道的Wistar大鼠中的稳定性相当。
  • 对MDA-MB-231细胞和分离肿瘤的定量实时聚合酶链反应分析显示TG2高表达,其他转谷氨酰胺酶表达很低。
  • PET显像显示[11C]1肿瘤摄取低(注射后40-60分钟约0.5 %ID/g)且洗脱相对较快。
  • [18F]2肿瘤摄取随时间稳定升高(注射后40-60分钟约1.7 %ID/g)。
  • 预先给予TG2抑制剂ERW1041E可降低肿瘤放射性浓度,使用未标记2时该抑制效果增强。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The protein cross-linking enzyme tissue transglutaminase (TG2; EC 2.3.2.13) is associated with the pathogenesis of various diseases, including cancer. Recently, the synthesis and initial evaluation of two high-potential radiolabelled irreversible TG2 inhibitors were reported by us. In the present study, these two compounds were evaluated further in a breast cancer (MDA-MB-231) tumour xenograft model for imaging active tissue transglutaminase in vivo. RESULTS: The metabolic stability of [11C]1 and [18F]2 in SCID mice was comparable to the previously reported stability in Wistar rats. Quantitative real-time polymerase chain reaction analysis on MDA-MB-231 cells and isolated tumours showed a high level of TG2 expression with very low expression of other transglutaminases. PET imaging showed low tumour uptake of [11C]1 (approx. 0.5 percentage of the injected dose per gram (%ID/g) at 40-60 min p.i.) and with relatively fast washout. Tumour uptake for [18F]2 was steadily increasing over time (approx. 1.7 %ID/g at 40-60 min p.i.). Pretreatment of the animals with the TG2 inhibitor ERW1041E resulted in lower tumour activity concentrations, and this inhibitory effect was enhanced using unlabelled 2. CONCLUSIONS: Whereas the TG2 targeting potential of [11C]1 in this model seems inadequate, targeting of TG2 using [18F]2 was achieved. As such, [18F]2 could be used in future studies to clarify the role of active tissue transglutaminase in disease.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. van der Wildt B, Wilhelmus MMM, Beaino W, et al. In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model. EJNMMI Res. 2018. PMID: 29802556. doi:10.1186/s13550-018-0388-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。